We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
Medica 2024
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Influenza-Respiratory Virus Panel Launched for Idylla platform

By LabMedica International staff writers
Posted on 09 Dec 2015
The majority of diagnostic tests currently used for respiratory viruses are rapid immunoassays which are chosen due to their low cost and convenience; however, one of the key downsides of these rapid tests is their poor sensitivity.

A fully automated, real-time polymerase chain reaction (PCR) based molecular diagnostics system, which is designed to offer fast and easy access to clinical molecular diagnostic information, anywhere and anytime has been launched for the diagnosis of respiratory infectious diseases.

Image: The Idylla fully automated, real-time polymerase chain reaction based molecular diagnostics system (Photo courtesy of Biocartis).
Image: The Idylla fully automated, real-time polymerase chain reaction based molecular diagnostics system (Photo courtesy of Biocartis).

The platform covers the entire process from sample to result in a time frame of 35 to 150 minutes with less than two minutes hands-on time. The platform is applicable for a wide range of clinical sample types and can analyze both ribonucleic acid (RNA) and DNA. A new panel for the platform is intended for the detection of various strains of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV).

The Idylla Respiratory IFV-RSV Panel (Biocartis Group NV; Mechelen, Belgium) is designed for the qualitative detection of nucleic acids of Influenza A, Influenza A subtype H1, Influenza A subtype H3, Influenza A subtype 2009 H1, H275Y mutation of Influenza A subtype 2009 H1, Influenza B and Respiratory Syncytial Virus (RSV) subtype A and RSV subtype B from nasopharyngeal swabs of adult and pediatric patients. The panel uses the Idylla molecular diagnostics platform to aid in the diagnosis of respiratory viral infection. The Idylla Respiratory IFV-RSV Panel received CE-IVD marking on November 18, 2015, and is being launched for commercial use in Europe and other countries recognizing the CE-marking. Janssen Diagnostics (Raritan, NJ, USA) has appointed Biocartis as co-exclusive worldwide distributor of the test.

Rudi Pauwels, PhD, CEO of Biocartis, said, “Collaboration is a key aspect of the strategy that we outlined at the time of our Initial Public Offering, in order to accelerate our menu development and speed up our commercial reach. Janssen has been a long-standing and very supportive partner of Biocartis. We are therefore delighted with the launch of such a high performance quality Idylla Respiratory IFV-RSV Panel. The combination of oncology and infectious disease tests demonstrates the versatility of our Idylla platform, one of the reasons why Janssen Diagnostics chose to work with Biocartis.”

Related Links:

Biocartis Group NV 
Janssen Diagnostics 



Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Gold Member
Pneumocystis Jirovecii Detection Kit
Pneumocystis Jirovecii Real Time RT-PCR Kit
New
LH ELISA
Luteinizing Hormone ELISA

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment